Analysts Set Sanofi (NASDAQ:SNY) Price Target at $63.33

Shares of Sanofi (NASDAQ:SNY - Get Free Report) have been assigned an average recommendation of "Buy" from the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, three have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $61.50.

Several research firms have recently weighed in on SNY. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price for the company. Morgan Stanley set a $56.00 target price on shares of Sanofi in a report on Monday. BNP Paribas began coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Finally, Guggenheim reiterated a "buy" rating on shares of Sanofi in a research note on Tuesday.

Sanofi Stock Performance

SNY traded up $0.61 during midday trading on Wednesday, reaching $50.37. The company had a trading volume of 992,108 shares, compared to its average volume of 2,401,889. The business has a 50-day moving average price of $51.79 and a two-hundred day moving average price of $51.93. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12. The stock has a market cap of $123.53 billion, a PE ratio of 20.21, a P/E/G ratio of 1.01 and a beta of 0.50. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.78 EPS. On average, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a dividend of $2.0369 per share. This represents a yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi's payout ratio is presently 57.14%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Brighton Jones LLC grew its stake in Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock worth $261,000 after buying an additional 1,869 shares in the last quarter. abrdn plc grew its stake in shares of Sanofi by 25.6% during the fourth quarter. abrdn plc now owns 314,180 shares of the company's stock valued at $15,153,000 after buying an additional 64,095 shares during the last quarter. Yousif Capital Management LLC increased its holdings in shares of Sanofi by 53.2% in the fourth quarter. Yousif Capital Management LLC now owns 59,611 shares of the company's stock worth $2,875,000 after buying an additional 20,690 shares during the period. Leo Wealth LLC lifted its stake in shares of Sanofi by 5.9% in the 4th quarter. Leo Wealth LLC now owns 26,669 shares of the company's stock valued at $1,286,000 after acquiring an additional 1,487 shares during the last quarter. Finally, Strategic Financial Concepts LLC purchased a new stake in Sanofi during the 4th quarter valued at about $667,000. 14.04% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.